Phaseline

Companies › Klus Pharma

Klus Pharma: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sacituzumab Govitecan (SKB264)
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 2Non-small Cell Lung Cancer; Solid Tumor; Epithelial Ovarian CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05816252Sacituzumab Govitecan (SKB264)Phase 2Non-small Cell Lung CancerOncologyDec 2026
NCT05642780Sacituzumab Govitecan (SKB264)Phase 2Solid TumorOncologyNov 2027
NCT04152499Sacituzumab Govitecan (SKB264)Phase 1Epithelial Ovarian CancerOncologyNov 2027

Targets

TACSTD2 (1) TOP1 (1)

Companies with the same targets

Daiichi Sankyo AstraZeneca Merck & Co. (MSD) Gilead Sciences Sichuan Kelun-Biotech Biopharmaceutical Sichuan Baili Pharmaceutical Lepu Biopharma BiOneCure Therapeutics Roche Fujifilm Pharmaceuticals U.S.A.

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.